Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudny, Miroslav, Zemanova, Jana, Khirsariya, Prashant, Borsky, Marek, Verner, Jan, Cerna, Jana, Oltova, Alexandra, Seda, Vaclav, Mraz, Marek, Jaros, Josef, Jaskova, Zuzana, Spunarova, Michaela, Brychtova, Yvona, Soucek, Karel, Drapela, Stanislav, Kasparkova, Marie, Mayer, Jiri, Paruch, Kamil, Trbusek, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959166/
https://www.ncbi.nlm.nih.gov/pubmed/30975914
http://dx.doi.org/10.3324/haematol.2018.203430

Ejemplares similares

Ejemplares similares